Researchers at Oxford University are beginning the first human trial of a personalised cancer treatment this week. The new drug, called CXD101, will be investigated alongside a new test which could predict which patients could be successfully treated by this class of drug.One of the major challenges in drug development is that each patient responds differently to treatment. The presence of a test which could determine whether a patient could be successfully treated by the drug would save time for patients with quickly-developing cancers, avoid the cost of unnecessary treatments and prevent damaging side effects.Lead researcher Nick La Thangue, Professor of Cancer Biology at the University of Oxford, said, “This is really the shape of things to come, and avoids the problem of testing drugs on patients who have little chance of benefiting from the treatment.”Professor Mark Middleton, the clinical lead for the trial and Professor of Experimental Cancer Medicine at Oxford University, said, “As we grapple with the affordability of new drugs we are always looking for ways to define who benefits from new treatments. If we can develop a test to say who should have a new drug we save the NHS money, patients from trying ineffective treatment and spare them side effects unless there’s a good chance of benefitting from treatment. For CXD101 there’s a long way to go to reach this goal, but by evaluating the biomarker from the start we stand the best chance of making it clinically useful.” The clinical trial will investigate CXD101, a next-generation histone deacetylase (HDAC) inhibitor. This blocks HDAC enzymes, which are important in the regulation of gene expression. Blocking these enzymes can stop cancer cells from multiplying, and may even kill cancer cells entirely. The test for the efficacy of the drug involves measuring the levels of a protein biomarker, HR23B. A high level of protein has been shown to make tumours more vulnerable to CXD101. The trial will involve 30-40 cancer patients. The first group will be given increasing doses of the drug to determine the most effective dose. The second group will be tested for the biomarker, and those with high levels will be treated with the best dose of the drug. This has significant implications for the future of cancer treatment, and can be effective on a wide spectrum of cancers for late-stage cancer patients. Professor La Thangue said, “Any cancer could be high in HR23B, from breast cancers to blood cancers, so we are screening a broad range of patients to identify anyone who might benefit.”Personalised medicine has been growing in popularity over the past decade to increase the efficiency of treatment. Samuel Kim, a first year medic at Oxford University, said: “Personalised medicine has been the next ‘big thing’ in medicine for a while now, and it is good to see novel treatments being trialled here at Oxford. However, I do worry that it will follow much the same story as gene therapy; something that promises so much, but has delivered so little.”The drug and associated test are still in Stage I of clinical trials, and it will be a minimum of 10 years before it is implemented as a treatment for cancer.Marco Narajos, online editor of Bang Science and a first year medic, commented, “Whilst the trial for CXD101 and the biomarker is exciting, we’re definitely not out of the woods yet. Certainly, we don’t know yet if it works, how much it will cost the NHS, and whether it will cause short term or long term side effects, and call me a cynic, but certainly it won’t be a panacea for cancer. The drug is meant for late-stage cancer patients, and potentially it will be useful to extend the lives of these patients, even if for a few months. We can still be hopeful, and I am excited to see the results of the trial.”
With their new box set Early Years: 1965-1972 coming out next week, Pink Floyd continues to build excitement by sharing new material. The newest such release takes us back to the band’s earliest days, when Syd Barrett was a member of their lineup.BBC 6 Music had the distinct honor of premiering a Barrett-penned track called “Vegetable Man,” a song written in 1965. Barrett also sings lead on the track, which was never officially released until now. Though “Vegetable Man” had circulated as a demo, the official release highlights Pink Floyd’s formative years.Listen to the recording via BBC 6 Music, here. You can scroll to the 51:15 mark to hear “Vegetable Man.”[H/T Consequence of Sound]
The Premier County take on the Déise men this Sunday in the National Hurling League semi-final in Nowlan Park. With Cathal Barrett, Kieran Bergin and John McGrath ruled out through injury and Seamus Callanan serving a one match suspension, O’Shea’s squad depth will once more be put to the test. But Waterford defender Connors feels Tipp’s fringe players are more than capable of delivering a big performance. Throw-in on Sunday is at four o’clock and Tipp FM will have full live coverage in association with Ormond Tiles, Summerhill, Nenagh and Kenyon Bar, Kenyon Street, Nenagh.
Lily Whites, Innkeepers, Club Inter and Jackson’s Hole are the top teams after the first half of the Nelson City Soccer League.Nelson City Soccer is currently taking a short break until resuming play in a few weeks.Lily Whites outlasted Red Dog and Dirty Dozen for the first half title in the Finley’s Ladies Rec League.The Whites edged Dirty Dozen 4-1 to complete the 12-game schedule with a 7-3-2 and a four-point advantage over Red Dog and Dirty Dozen, deadlocked for second spot.Selkirk Eyecare finished fourth. In the Leo’s Men’s Open League, Innkeepers made it look easy as the defending league champs cruised to a 9-1 record and a 13-point advantage over Kootenay Co-op.The L.V. Rogers Bombers finished third, two points in front of Old Dogs FC.Club Inter dropped only four points in the first half of the Jackson’s Hole Men’s Masters League.Club Inter finished with a 9-1-2 mark, good enough for a five-point advantage over defending playoff champ, Jackson’s Hole.Bia Boro is third followed by Red Dog, Ted Allen’s and Real Nelson.Jackson’s Hole lost only two games to dominate the Bogustown Co-ed standings over Bogustown.Jackson’s finished with a 7-2-1 record, eight points in front of Bogustown.Free Ride and Ted Allen’s finished tied for third.
STAR 4 13&O – Courtney Shrieves, Morgan SaboSTAR 5 U13 – Charly DeFouwSTAR 5 13&O – Breanna TomilinInterpretive Events:Pre-Introductory Interpretive – Charly DeFouwIntroductory Interpretive – Morgan SaboBronze Interpretive – Breanna TomilinDance Solo Events:Jr. Bronze Dance Solo – Lila McKechnieSr. Bronze Dance Solo – Courtney ShrievesSr. Silver Dance Solo – Christina Champlin, Breanna TomilinElements Events:Elements 1 – Helena Keating, Isabella Kroker-Kimber, Morgan SaboElements 2 – Charly DeFouw, Breanna TomilinFor more info and photos visit nelsonfigureskatingclub.ca Free Skate Events:STAR 1 – Aurora Panko-Dool, Lulu Nyiti, Courtney DonaldsonSTAR 2-Tia Berens, Leo Measures, Lila McKechnie, Helena Keating, Hannah CorvenSTAR 3 – Isabella Kroker-Kimber A slate 14 of competitors the Nelson Figure Skating Club will test their mettle this weekend at the West Kootenay Invitational in Rossland.The meet marks the second major competition in the Kootenay Region giving skaters another opportunity to have their performances rated by a team of judges. In addition many skaters will be attempting to pass Dance and Elements Test.“Our senior skaters are looking to improve on their scores from the East Kootenay Invitational in Kimberley this past November,” said coach Sarah Gower.“They’re building towards hitting their peaks for the STARSkate Super Senior Series Final in Kelowna this March where provincial champions at all levels will be crowned.”For those skaters competing at STAR 4 and over their marks will also count towards qualifying for the Provincial Development Camp later this year.“The is the busiest time of the season,” adds coach Yoshie Measures. “We have kids working on freeskate and interpretive programs as well as taking tests. For our younger skaters Rossland will be their first taste of what a competition is like.”